Source: The Business Journals: Seattle

Icosavax: AstraZeneca completes $1.1B acquisition of UW spinout Icosavax

Icosavax is targeting viruses that can cause severe respiratory infection.

Read full article »
Icosavax's Competitors | Icosavax's News | Icosavax's Financials
Stay up-to-date with the latest news on Icosavax
Annual Revenue
$100K-5.0M
Employees
25-100
Adam K. Simpson's photo - President & CEO of Icosavax

President & CEO

Adam K. Simpson

CEO Approval Rating

88/100

Read more
Stay up-to-date with the latest news on Icosavax